936-P: The Effect of Switching the Medtronic MiniMed 780G Insulin Pump to the “Optimal” Setting

Introduction and Objective: The most promising method for insulin delivery in individuals with type 1 diabetes mellitus (T1DM) is the automated insulin pump therapy. In Hungary, the only automated insulin pump reimbursed by the National Health Insurance Company is the Medtronic Minimed 780 G (MM780G) hybrid closed-loop system. Recently, optimal adjustment methods for the MM780G have been established, determining that a glucose target value (GT) of 100 mg/dl and an active insulin time (AIT) of 2 hours are ideal. Methods: We analyzed the settings of our patients using the MM780G and encouraged them to adjust to the optimal settings. We then evaluated sensor data from two weeks before and after the adjustments. Results: Our department's database includes 164 T1DM individuals treated with MM780G, of whom 82 were not yet on optimal settings. Most of these patients (80%) beforehand had a GT of 100 mg/dl; however, their AIT exceeded 2 hours (with 8 cases having AIT >2.5 hours and 74 cases at AIT = 2.5 hours). Adjusting the settings to optimal parameters was recommended for these patients, and 58 of them could successfully be persuaded to change their AIT to 2 hours. After this adjustment, the time spent in the target range (TIR) increased from 73.8% to 77.0%, and the time in the tight range (TITR) rose from 48.7% to 52.3% (p < 0.05 for both). The time spent above the target range also improved significantly, while the time spent below the target range and variability did not change substantially. The glucose management indicator (GMI) showed a slight but significant decrease (p < 0.01) from 6.9% to 6.8%. Conclusion: Our data indicate that even a minor adjustment, such as changing the AIT from ≥ 2.5 hours to 2 hours, can significantly enhance the sensor metrics achieved with the MM780G. The improvement in TIR was attributed to an increase in the time spent in euglycemia, reflected in the TITR. Disclosure J.T. Kis: Speaker's Bureau; Novo Nordisk, Lilly Diabetes, Sanofi, Boehringer-Ingelheim, AstraZeneca, KRKA, Berlin-Chemie AG. C. Fekete: None. K.R. Arapovicsné Kis: None. G.G. Tomasics: None. L. Schandl: None. G. Winkler: None.